EUVIMEDEUVIMED entdecken
Open Access

Hematologic Malignancies of the Breast: A Contemporary Series Investigating Incidence, Presentation, Accuracy of Diagnosis on Core Needle Biopsy, and Hormone Receptor Expression

Marie-Christine Guilbert, Jason L Hornick, Sona A Chikarmane, Susan C Lester

Breast Cancer: Basic and Clinical Research · 2019-01 · 13

DOI: 10.1177/1178223419830982 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer: Basic and Clinical Research, online erschienen am 21.02.2019. Verfasst von Marie-Christine Guilbert und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Distinguishing breast hematologic malignancies in core needle biopsies from other entities can be challenging. Misclassification as a breast carcinoma could result in inappropriate treatment. The aim of this study was to characterize the types, incidence, and helpful diagnostic features of hematologic malignancies of the breast.

Design

All hematologic malignancies of the breast diagnosed at our institution from 2004 to 2017 were identified. Clinical notes, imaging, and slides were reviewed. Immunohistochemical analysis of estrogen receptor α (ERα), estrogen receptor β (ERβ), and androgen receptor (AR) was performed when tissue was available.

Results

In all, 43 hematologic malignancies from biopsies of 37 women and 6 men were identified. Core needle biopsies (35 or 81%) were more common than excisions (8 or 19%). For 14 patients (40%), the core biopsy was the first diagnosis of a hematologic malignancy. Diagnoses included 37 lymphomas (7 primary), 4 leukemias, and 2 myelomas. There was 1 misdiagnosis of carcinoma. Low positivity for hormone receptors was observed in a minority of lymphomas. A definitive diagnosis of hematologic malignancy was made in 31 (89%) of the core needle biopsies. Only 3 patients undergoing core biopsy required excision for diagnosis.

Conclusions

Most of the hematologic malignancies of the breast are currently diagnosed on core needle biopsy and 40% of patients do not have a prior history. To avoid errors, pathologists need to be aware of diagnostic features and morphologic mimics. A hematologic malignancy should be considered if tumor cells are discohesive, carcinoma in situ is absent, and hormone expression is low or absent.

Schlagwörter

Stichwörter der Autor:innen

breast hematologic malignanciesbreast lymphoma

Autor:innen und Institutionen

  • Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
  • Department of Pathology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada.
  • Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.

Zitieren

APA

Guilbert, M. C., Hornick, J. L., Chikarmane, S. A., & Lester, S. C. (2019). Hematologic Malignancies of the Breast: A Contemporary Series Investigating Incidence, Presentation, Accuracy of Diagnosis on Core Needle Biopsy, and Hormone Receptor Expression. Breast Cancer: Basic and Clinical Research, 13. https://doi.org/10.1177/1178223419830982

Vancouver

Guilbert MC, Hornick JL, Chikarmane SA, Lester SC. Hematologic Malignancies of the Breast: A Contemporary Series Investigating Incidence, Presentation, Accuracy of Diagnosis on Core Needle Biopsy, and Hormone Receptor Expression. Breast Cancer: Basic and Clinical Research. 2019;13. doi:10.1177/1178223419830982

BibTeX
@article{Guilbert2019,
  author = {Guilbert, Marie-Christine and Hornick, Jason L and Chikarmane, Sona A and Lester, Susan C},
  title = {Hematologic Malignancies of the Breast: A Contemporary Series Investigating Incidence, Presentation, Accuracy of Diagnosis on Core Needle Biopsy, and Hormone Receptor Expression},
  journal = {Breast Cancer: Basic and Clinical Research},
  year = {2019},
  volume = {13},
  doi = {10.1177/1178223419830982}
}
Kostenlos starten →